Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Arrangement Combines Immatics’ XPRESIDENT® Technology and Amgen’s Proprietary Bispecific Antibody Platform
Immatics to Receive $30 Million Upfront and Potentially Over $1 Billion in Milestone Payments Plus Royalties

read more

Immatics announces results of IMPRINT phase 3 clinical trial investigating the addition of IMA901 to standard first-line therapy with sunitinib for advanced/metastatic RCC

Immatics announces results of IMPRINT phase 3 clinical trial investigating the addition of IMA901 to standard first-line therapy with sunitinib for advanced/metastatic RCC

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company and a global leader in cancer immunotherapy, announced today the results of a pivotal phase 3 clinical trial with IMA901

read more

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics US, Inc. has secured over $60m in total funding – more than $40m from the parent company Immatics Biotechnologies GmbH and a $19.7 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT)

read more